|
Monday 13th June 2022 |
Text too small? |
Comvita now forecasts that its full year reported EBITDA is expected to be in a range of $28.5M –$30.0M (previous guidance operating EBITDA $27M – $30M). For clarity, this new range includes Comvita absorbing the impact of previously disclosed one off M&A costs of circa $1M. Comvita is also forecasting double digit growth in Net Profit after Tax for the full year versus the prior corresponding period.
Commenting David Banfield “I am delighted with the momentum that we are experiencing in the business and the ongoing resilience of our focused business model. Consumers continue to choose premium solutions from Comvita as a key part of helping to build natural immunity. This updated guidance is particularly encouraging given the material disruption to offline trade in mainland China through the last quarter and is testament to the quality of our team around the world and at home in Aotearoa, New Zealand”.
Ends.
Comvita full year guidance update – FY22
No comments yet
SPK - Spark notes Government spectrum policy announcement
SML - Synlait finalises refinancing and advises changes to balan
KMD strengthens balance sheet with debt refinance
GXH - Green Cross Health Limited - Annual Shareholders' Meeting
VGL - Cineplexx Europe signs to Operational Excellence
STU - Steel & Tube - Director Resignation - Steve Reindler
Ryman Healthcare Limited Notice of Meeting 2026
Spark New Zealand FY26 Results Announcement Date
OCA - Oceania bond offer - interest rate set
VNT - Appointment of Managing Director and Group CEO of Ventia